1. Search Result
Search Result
Results for "

p53<sup>R175H</sup>, P53<sup>Y220C</sup>, p53<sup>-/-</sup>, p53<sup>WT</sup>

" in MedChemExpress (MCE) Product Catalog:

1608

Inhibitors & Agonists

6

Screening Libraries

2

Fluorescent Dye

4

Biochemical Assay Reagents

44

Peptides

1

Inhibitory Antibodies

69

Natural
Products

49

Recombinant Proteins

873

Isotope-Labeled Compounds

23

Antibodies

14

Click Chemistry

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148416

    MDM-2/p53 Cancer
    p53 Activator 7 is a p53 mutation Y220C (MDM-2/p53) activator with an EC50 of 104 nM. p53 Activator 7 can bind to p53 mutant and restore its ability to bind DNA (WO2022213975A1; Example B-1) . p53 Activator 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    p53 Activator 7
  • HY-145759

    MDM-2/p53 Cancer
    Mutant p53 modulator-1 is a mutant p53 modulator. Mutant p53 modulator-1 reduces the progression of cancers that contain a p53 mutation (extracted from patent WO2021231474A1, compound 231B) .
    Mutant p53 modulator-1
  • HY-160449

    MDM-2/p53 Cancer
    p53 Activator 10 (Example C-2) is a compound that targets the y220c mutant of p53. p53 Activator 10 activation is involved in the downstream effects of tumor suppression .
    p53 Activator 10
  • HY-160450

    MDM-2/p53 Cancer
    p53 Activator 11 (compound A-1) is a potent p53 activator with an EC50 value of 0.478 µM for p53 (Y220C). p53 Activator 11 has the potential for the research of cancer .
    p53 Activator 11
  • HY-158151

    MDM-2/p53 Cancer
    p53 Activator 12 (compound 510B) is a potent p53 activator. p53 Activator 12 binds to mutant p53 and restores the ability of the p53 mutant to bind DNA .
    p53 Activator 12
  • HY-P5343

    p53 Consensus binding sequence

    MDM-2/p53 Others
    p53 CBS (p53 Consensus binding sequence) is a biological active peptide. (p53 consensus DNA binding site)
    p53 CBS
  • HY-156919

    MDM-2/p53 Cancer
    p53 Activator 8 (compound 5) is a p53 activator. p53 Activator 8 has potent anti-proliferative activity against MCF7 breast cancer cell lines with an IC 50 value of 0.5 μM .
    p53 Activator 8
  • HY-168636

    DNA Methyltransferase MDM-2/p53 Cancer
    p53 Activator 13 (compound 11) is a 6mA methyltransferase CamA inhibitor and a p53 activator. p53 Activator 13 intercalates into CamA-bound DNA via the minor groove, causing a conformational shift that moves the catalytic domain away from the DNA and elicits DNA damage response via p53 activation. p53 Activator 13 can be utilized in cancer research .
    p53 Activator 13
  • HY-146095

    MDM-2/p53 DNA/RNA Synthesis Apoptosis Cancer
    p53 Activator 2 (compound 10ah) intercalats into DNA and results in significant DNA double-strand break.p53 Activator 2 increases the expression of p53, p-p53, CDK4, p21 to cause cell cycle arrest at G2/M phase.p53 Activator 2 induce apoptosis and significantly down-regulates the anti-apoptosis proteins Bcl-2, Bcl-xL and the levels of cyclin B1.p53 Activator 2 has anti-proliferation activity against MGC-803 cells, with an IC50 of 1.73 µM. p53 Activator 2 displays potent anticancer efficiency against MGC-803 xenograft tumors models .
    p53 Activator 2
  • HY-P1755

    MDM-2/p53 Cancer
    p53 (17-26) is amino acids 17 to 26 fragment of p53. p53 (17-26) is mdm-2-binding domain .
    p53 (17-26)
  • HY-148404

    MDM-2/p53 Cancer
    p53 Activator 5 (compound 134A) is a potent p53 activator with a SC150 value of <0.05 mM. p53 Activator 5 can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA. p53 Activator 5 shows anti-tumor activity . p53 Activator 5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    p53 Activator 5
  • HY-148402

    MDM-2/p53 Cancer
    p53 Activator 3 (compound 87A) is a potent p53 activator with a SC150 value of <0.05 mM. p53 Activator 3 can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA. p53 Activator 3 shows anti-tumor activity . p53 Activator 3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    p53 Activator 3
  • HY-160448

    Others Cancer
    p53 Activator 9 (example D-4) is a p53 activator with EC50 of 1.699μM .
    p53 Activator 9
  • HY-70027A

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    p53 and MDM2 proteins-interaction-inhibitor dihydrochloride is an inhibitor of the interaction between p53 and MDM2 proteins.
    p53 and MDM2 proteins-interaction-inhibitor dihydrochloride
  • HY-P1755F

    MDM-2/p53 Others
    p53 (17-26), FITC labeled is a biological active peptide.
    p53 (17-26), FITC labeled
  • HY-70027

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    p53 and MDM2 proteins-interaction-inhibitor (chiral) (Compound 32) is an inhibitor of the interaction between p53 and MDM2 proteins.
    p53 and MDM2 proteins-interaction-inhibitor (chiral)
  • HY-70028

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    p53 and MDM2 proteins-interaction-inhibitor (racemic) (Compound 2j) is an inhibitor of the interaction between p53 and MDM2 proteins.
    p53 and MDM2 proteins-interaction-inhibitor (racemic)
  • HY-122578

    MDM-2/p53 Cancer
    P53R3 is a potent p53 reactivator and restores sequence-specific DNA binding of p53 hot spot mutants, including p53 R175H, p53 R248W and p53 R273H. P53R3 induces p53-dependent antiproliferative effects with much higher specificity than PRIMA-1. P53R3 enhances the recruitment of wild-type p53 and p53 M237I to several target gene promoters. P53R3 strongly enhances the mRNA, total protein and cell surface expression of the death receptor death receptor 5 (DR5). P53R3 is used for cancer research .
    P53R3
  • HY-161039

    MDM-2/p53 Cancer
    MDM2-p53-IN-18 (Compd A-7b) is a MDM2-p53 interaction inhibitor .
    MDM2-p53-IN-18
  • HY-161041

    MDM-2/p53 Cancer
    MDM2-p53-IN-20 (Compd B-11j) is a synthetic MDM2-p53 interaction inhibitor that play an important role in cancer .
    MDM2-p53-IN-20
  • HY-151170

    MDM-2/p53 Apoptosis Cancer
    MDM2/4-p53-IN-2 (2q) is a potent dual MDM2/ MDM4 inhibitor and p53 activator with the IC50 values of 70.7 nM for MDM2- p53 and 81.4 nM for MDM4-p53 complexes. MDM2/4-p53-IN-2 regulates the cell cycle, induces cell apoptosis and has anticancer activity .
    MDM2/4-p53-IN-2
  • HY-161040

    Others Cancer
    MDM2-p53-IN-19 (Compound A-8d) is a chemical intermediate that can be used to synthesize inhibitors of the MDM2-p53 interaction with anticancer activity .
    MDM2-p53-IN-19
  • HY-120373

    MDM-2/p53 Cancer
    MB710, an aminobenzothiazole derivative, is a stabilizer of oncogenic p53 mutation Y220C. MB710 binds tightly to the Y220C pocket and stabilizes p53-Y220C, with a Kd of 4.1 μM. MB710 shows anticancer activity in p53-Y220C cell lines .
    MB710
  • HY-159606

    MDM-2/p53 Cancer
    MS182 (compound 11) is an acetylation targeting chimera (AceTAC) designed based on p53 Y220C stabilizer and targeting p53 Y220C. MS182 is composed of p53 Y220C and p300/CBP binders, respectively, coupled by a linker. MS182 forms a ternary complex with p300/CBP acetyltransferase and p53 Y220C in a time- and concentration-dependent manner, effectively acetylating lysine at position 382 of p53 Y220C (ACE50: 1.52 μM). MS182 also exhibited considerable bioavailability in mice, with GI50 values of 2.16 μM and 1.83 μM for BxPC3 (p53 Y220C/-) and NUGC (p53 Y220C/+), respectively .
    MS182
  • HY-148833

    MDM-2/p53 Cancer
    MDM2-p53-IN-16 is a MDM2-p53 complex inhibitor with an IC50 value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research .
    MDM2-p53-IN-16
  • HY-162927

    MDM-2/p53 Apoptosis Cancer
    p53-MDM2-IN-6 (Compound 10a), a LSM-83177 hydrazone analog, is a potent p53-MDM2 inhibitor with an IC50 value of 11.08 µg/mL. p53-MDM2-IN-6 arrests the cell cycle in the S phase and induces early and late Apoptosis with antiproliferative activity against HT29 cell lines with an IC50 value of 10.44 µg/mL. p53-MDM2-IN-6 inhibits p53-MDM2 interaction with increment in p-53 level and decrease the expression of GST enzymes. p53-MDM2-IN-6 is promising for research of colorectal cancer .
    p53-MDM2-IN-6
  • HY-151171

    MDM-2/p53 Cancer
    MDM2/4-p53-IN-3 is a MDM2/4-p53 protein-protein interactions (PPIs) inhibitor (IC50s: 18.5 nM for MDM2-p53, 14.8 nM for MDM4-p53). MDM2/4-p53-IN-3 can be used in the research of cancers, such as colon cancer .
    MDM2/4-p53-IN-3
  • HY-151169

    MDM-2/p53 Cancer
    MDM2/4-p53-IN-1 is a potent MDM2-p53 and MDM4-p53 inhibitor with IC50 values of 35.9, 57.4 nM, respectively. MDM2/4-p53-IN-1 shows antiproliferative activity .
    MDM2/4-p53-IN-1
  • HY-163661

    Apoptosis Autophagy MDM-2/p53 Cancer
    p53-MDM2-IN-5 (compound 5a) is a potent p53-MDM2 inhibitor. p53-MDM2-IN-5 induces apoptosis, autophagy and DNA damage. p53-MDM2-IN-5 induces cell cycle arrest at S and G2/M phases. p53-MDM2-IN-5 shows anti-tumor activity .
    p53-MDM2-IN-5
  • HY-151172

    MDM-2/p53 Apoptosis Cancer
    MDM2-p53-IN-15 is a MDM2-p53 inhibitor with an IC50 value of 26.1 nM. MDM2-p53-IN-15 inhibits the proliferation of various cancer cells and induces cell apoptosis. MDM2-p53-IN-15 can be used for the research of cancer .
    MDM2-p53-IN-15
  • HY-168606A

    MDM-2/p53 Cancer
    p53-MDM2-IN-7 (compound 6d) (hydrochloride) is a p53-MDM2 inhibitor. p53-MDM2-IN-7 has an IC50 value of 8.13 μM against A549 cells. p53-MDM2-IN-7 can be used in anti-cancer research .
    p53-MDM2-IN-7 hydrochloride
  • HY-145907

    MDM-2/p53 Cancer
    p53-HDM2-IN-1 is a potent inhibitor of p53-HDM2 protein-protein interaction, with an IC50 of 0.103 μM. p53-HDM2-IN-1 can be used for the research of cancer .
    p53-HDM2-IN-1
  • HY-W340313

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    p53-MDM2-IN-4 (Example 4) is an inhibitor of p53-MDM2/X protein interaction, with a Ki value of 3.079 μM. p53-MDM2-IN-4 can be used in anti-tumor research .
    p53-MDM2-IN-4
  • HY-W340839

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    p53-MDM2-IN-1 (Example 30) is an inhibitor of p53-MDM2/X protein interaction with an Ki value of 23.35 µM. p53-MDM2-IN-1 can be used for anti-tumor research .
    p53-MDM2-IN-1
  • HY-116052

    MDM-2/p53 NF-κB Cancer
    p53-MDM2-IN-2 (Compound 5q) is an orally active p53-MDM2 inhibitor with a Ki value of 0.25 μM. p53-MDM2-IN-2 exerts antitumor activity by inhibiting NF-κB pathway .
    p53-MDM2-IN-2
  • HY-121893

    MDM-2/p53 NF-κB Cancer
    p53-MDM2-IN-3 (Compound 5s) is an orally active p53-MDM2 inhibitor with a Ki value of 0.25 μM. p53-MDM2-IN-3 exerts antitumor activity by inhibiting NF-κB pathway .
    p53-MDM2-IN-3
  • HY-145900

    MDM-2/p53 Cancer
    S100A2-p53-IN-1 (compound 51) is a S100A2-p53 interactions inhibitor. S100A2 is a Ca 2+ binding protein with implications in cell signaling and is known to be upregulated in pancreatic cancer. S100A2-p53-IN-1 can inhibit the growth of the MiaPaCa-2 pancreatic cancer cell line (GI 50 of 1.2-3.4 μM) .
    S100A2-p53-IN-1
  • HY-144105

    MDM-2/p53 Cancer
    NSC405640 is a potent inhibitor of the MDM2-p53 interaction. NSC405640 rescues structural p53 mutations. NSC405640 selectively inhibits the growth of cell lines with wild-type p53 .
    NSC405640
  • HY-156967

    MDM-2/p53 Cancer
    BAY 1892005 is a regulator of p53 protein and acts on p53 condensates without causing mutant p53 reactivation .
    BAY 1892005
  • HY-W034419

    MDM-2/p53 Apoptosis Cancer
    STIMA-1 can stimulate mutant p53 DNA binding in vitro and induce expression of p53 target proteins and trigger apoptosis in mutant p53-expressing human tumor cells .
    STIMA-1
  • HY-155974

    MDM-2/p53 Cancer
    MeOIstPyrd is an anti-skin cancer agent. MeOIstPyrd inhibits cell proliferation, migration, and spheroid formation by activating the mitochondrial intrinsic apoptotic pathway. MeOIstPyrd induces DNA damage. MeOIstPyrd activates p53, and increases the half-life of p53 and stabilizes p53 by phosphorylating it at ser15. MeOIstPyrd binds to MDM2 in the p53 sub-pocket and blocks p53-MDM2 interaction .
    MeOIstPyrd
  • HY-141584

    MDM-2/p53 Cancer
    ATSP-7041, a selective dual peptide inhibitor of MDM2 and MDMX, effectively reactivates the p53 tumor suppressor pathway in a mechanism-dependent manner in p53-positive cancers .
    ATSP-7041
  • HY-162247

    MDM-2/p53 Cancer
    MDM2-IN-26 (compound A3) is an MDM2 inhibitor that can activate the tumor suppressor function of p53 by blocking the interaction between MDM2 and p53 (MDM2 is the main negative regulator of p53). MDM2-IN-26 can be used for cancer research .
    MDM2-IN-26
  • HY-126905

    NSC328784

    Reactive Oxygen Species Cancer
    ZMC3 (NSC328784) is a zinc chelator. ZMC3 shows Zinc metallochaperone properties. ZMC3 shows enhanced sensitivity in p53-R175H mutant cells. ZMC3 increases the cell ROS level .
    ZMC3
  • HY-A0280

    Benzylhexamethylenetetramine bromide

    MDM-2/p53 FAK Cancer
    Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator with anticancer effects. Roslin 2 bromide binds FAK, disrupts the binding of FAK and p53 .
    Roslin 2 bromide
  • HY-14967

    MDM-2/p53 Cancer
    NSC 66811 is a MDM2-p53 inhibitor, with a Ki of 120 nM for binding to MDM2 .
    NSC 66811
  • HY-108637

    MDM-2/p53 Cancer
    PhiKan 083 is a carbazole derivative, which binds to the surface cavity and stabilizes Y220C (a p53 mutant), with a Kd of 167 μM. PhiKan 083 can be used for cancer research .
    PhiKan 083
  • HY-148408

    Sirtuin Cancer
    SIRT2-IN-11 (AEM1) is a selective SIRT2 inhibitor with an IC50 value of 18.5 μM. SIRT2-IN-11 p53-dependently induces apoptosis, activates expression of CDKN1A, PUMA and NOXA, and increases acetylation of p53. SIRT2-IN-11 can be used for the research of p53-related cancers .
    SIRT2-IN-11
  • HY-153767

    MDM-2/p53 Cancer
    PK095 is a p53 mutant stabilizer. PK095 can be used for research of cancer .
    PK095
  • HY-113843

    Others Cancer
    RETRA (hydrobromide) is a mutant p53-dependent activator of p73 that can inhibit cancer cells carrying mutant p53. RETRA (hydrobromide) increases the expression level of p73, induces transcriptional activation of several common to transcriptional targets p53 and p73, which leads to mutant p53- and p73-dependent inhibition of tumor growth, reduction of colony formation and induction of effector caspases .
    RETRA hydrobromide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: